Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine - PubMed (original) (raw)
. 2000 Nov;9(11):1155-62.
Affiliations
- PMID: 11097222
Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine
K R Lawson et al. Cancer Epidemiol Biomarkers Prev. 2000 Nov.
Abstract
The nonsteroidal anti-inflammatory drug sulindac and the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) are both potent inhibitors of colon carcinogenesis in experimental models of this disease. The combination of these two agents is undergoing evaluation as a strategy for colon cancer chemoprevention in humans with resected colon polyps. We evaluated the effects of the major sulfide and sulfone metabolites of sulindac and DFMO alone, or in combinations, on the growth and survival of Caco-2 colon cancer-derived cells and in clones of these cells transfected with an activated K-ras oncogene. Both the sulfide and sulfone metabolites of sulindac reduced cell viability, measured by colony-forming assays, primarily by inducing apoptosis. Expression of an activated K-ras oncogene caused cells treated with either sulindac sulfide or sulfone to undergo apoptosis earlier than nontransfected controls. However, clonogenic survival, measured 2 weeks after drug treatment, was the same in both Caco-2 and ras-transfected Caco-2 cells treated with sulindac metabolites. A 24-h treatment with DFMO caused a dose-dependent decrease in the colony-forming ability of cells expressing an activated K-ras but had no effect on the viability of the parental Caco-2 cells. The DFMO-dependent decrease in colony formation in K-ras-activated cells occurred in the absence of apoptosis. Assessment of cell survival by colony-forming assays indicated that these two agents acted in an additive manner when combined. These data indicate that K-ras can influence the kinetics of apoptosis induction by sulindac metabolites and cell survival in response to DFMO. However, cytotoxicity induced by these agents occurs via unique mechanisms. These studies suggest that the combination of DFMO and sulindac may be useful in human cancer prevention strategies.
Similar articles
- Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R, Ahnen DJ. Piazza GA, et al. Cancer Res. 1997 Jun 15;57(12):2452-9. Cancer Res. 1997. PMID: 9192825 - Sulfone metabolite of sulindac inhibits mammary carcinogenesis.
Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, Pamukcu R, Ahnen DJ. Thompson HJ, et al. Cancer Res. 1997 Jan 15;57(2):267-71. Cancer Res. 1997. PMID: 9000566 - The new sulindac derivative IND 12 reverses Ras-induced cell transformation.
Karaguni IM, Herter P, Debruyne P, Chtarbova S, Kasprzynski A, Herbrand U, Ahmadian MR, Glüsenkamp KH, Winde G, Mareel M, Möröy T, Müller O. Karaguni IM, et al. Cancer Res. 2002 Mar 15;62(6):1718-23. Cancer Res. 2002. PMID: 11912145 - Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL Jr, Gerner EW. Meyskens FL Jr, et al. Clin Cancer Res. 1999 May;5(5):945-51. Clin Cancer Res. 1999. PMID: 10353725 Review. - Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention.
Gerner EW, Meyskens FL Jr, Goldschmid S, Lance P, Pelot D. Gerner EW, et al. Amino Acids. 2007 Aug;33(2):189-95. doi: 10.1007/s00726-007-0515-2. Epub 2007 Mar 30. Amino Acids. 2007. PMID: 17396214 Review.
Cited by
- Eflornithine for chemoprevention in the high-risk population of colorectal cancer: a systematic review and meta-analysis with trial sequential analysis.
Yang L, Wang Y, Hu S, Wang X. Yang L, et al. Front Oncol. 2023 Nov 15;13:1281844. doi: 10.3389/fonc.2023.1281844. eCollection 2023. Front Oncol. 2023. PMID: 38033490 Free PMC article. - Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
Mattox TE, Chen X, Maxuitenko YY, Keeton AB, Piazza GA. Mattox TE, et al. Int J Mol Sci. 2019 Dec 24;21(1):141. doi: 10.3390/ijms21010141. Int J Mol Sci. 2019. PMID: 31878223 Free PMC article. Review. - Cancer pharmacoprevention: Targeting polyamine metabolism to manage risk factors for colon cancer.
Gerner EW, Bruckheimer E, Cohen A. Gerner EW, et al. J Biol Chem. 2018 Nov 30;293(48):18770-18778. doi: 10.1074/jbc.TM118.003343. Epub 2018 Oct 24. J Biol Chem. 2018. PMID: 30355737 Free PMC article. Review. - Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas.
Chang WL, Jackson C, Riel S, Cooper HS, Devarajan K, Hensley HH, Zhou Y, Vanderveer LA, Nguyen MT, Clapper ML. Chang WL, et al. Gut. 2018 Jul;67(7):1290-1298. doi: 10.1136/gutjnl-2017-313942. Epub 2017 Nov 9. Gut. 2018. PMID: 29122850 Free PMC article. - Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention?
Rice PFS, Ehrichs KG, Jones MS, Chen H, Hsu CH, Abril ER, Nagle RB, Besselsen DG, Barton JK, Ignatenko NA. Rice PFS, et al. Cancer Prev Res (Phila). 2018 Jan;11(1):16-26. doi: 10.1158/1940-6207.CAPR-17-0230. Epub 2017 Nov 8. Cancer Prev Res (Phila). 2018. PMID: 29118162 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous